2Robb M A,Racoosin J A,Sherman R,et al.The US Food and Drug Administration's Sentinel Initiative:Expanding the horizons of medical product safety[J].Pharmacoepidemiology and Drug Safety, 2012,21($1 ) :9-11.
3Stang P E,Ryan P B,Racoosin J A,et al. Advancing the science for active surveillance:rationale and design for the Observational Medical Outcomes Partnershop[J]. Annals of Internal Medicine, 2010,153 (9):600-606.
4Takahashi Y24ishida Y,Asai S. Utilization of health care databases for Pharmacoepidemiology[J].Eur J Clin Pharmacol, 2012,68(2 ):123-129.
5Michael D Murray.Use of Data from Electronic Health Records for pharmacoepidemiology [J].Curr Epidemiol Pep, 2014,1:186-193.
6Hennessy S.Use of health care databases in pharmacoepidemiology [J]. Basic & Clinical Pharmacology & Toxicology, 2006,98,311-313.
7FDA.Prescription Drug User Fee Act (PDUFA) IV Drug Safety Five Year Plan[EB/OL]. (2010-06) [2014-12-23].www.fda.gov/ downloads/forindustry/userfees/prescriptiondruguserfee/ucm- 216354.pdf.
8Louise Wood,Carlos MartinezThe general practice research databas~ role in pharmacovigilance[J].Drug Safety, 2004,27(12):871-881.
9Rachel A. Charlton, John G. Weil, Marianne C. Cunnington, et al. Identifying Major Congenital Malformations in the UK General PracficeResearchDatahase (GPRD){J]. Drug Saf,2010,33(9): 741-750.
10C.Cooper, M.Steinbuch, R.Stevenson, et al. The epidemiology of osteonecrosis: findings from the GPRD and THIN databases in the UK[J].Osteoporos Int,2010,21(4):569-577.
